ACADIA Pharmaceuticals Inc Announces Outcome of FDA Advisory Committee for NUPLAZID® Transcript
Okay. Good morning. I assume we're okay to start. Good morning, and welcome. I would first like to remind everyone to please mute your line when you're not speaking. For media and press, the FDA press contact is April Grant. Her e-mail and phone number are currently displayed.
My name is Raj Narendran, and I will be chairing this meeting. I would now call the June 17, 2022, Psychopharmacologic Drug Advisory Committee Meeting to order. Dr. Joyce Frempong is the designated Federal Officer for this meeting and will begin with the introductions.
Good morning. My name is Joyce Frempong, and I'm the designated Federal Officer for this meeting. When I call your name, please introduce yourself by stating your name and affiliation Dr. Robert Baker.
Good morning. This is Robert Baker, Deputy Chief Medical Officer at Eli Lilly and Company, so I'm the industry representative.
Dr. Walter Dunn.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
